Role of high‐volume plasmapheresis in the management of paediatric acute liver failure

Johannes Hilberath,Vittoria Camelli,Christiane Hofer,Steffen Hartleif,Silvio Nadalin,Maren Peters,Matthias Kumpf,Andrea Bevot,Matthias Zirngibl,Marcus Weitz,Ekkehard Sturm
DOI: https://doi.org/10.1002/jpn3.12211
2024-04-17
Journal of Pediatric Gastroenterology and Nutrition
Abstract:Objectives Paediatric acute liver failure (PALF) is a life‐threatening disease. Management aims to support hepatic regeneration or to bridge to liver transplantation. High‐volume plasmapheresis (HVP) removes protein‐bound substances, alleviates inflammation, and improves survival in adult acute liver failure. However, experience with HVP in PALF is limited. Aim of this study is to report on feasibility, safety, efficacy and outcomes of HVP in PALF. Methods Retrospective observational study in children with PALF. HVP was performed upon identification of negative prognostic indicators, in toxic aetiology or multiorgan failure (MOF). Exchanged volume with fresh‐frozen plasma corresponded to 1.5–2.0 times the patient's estimated plasma volume. One daily cycle was performed until the patient met criteria for discontinuation, that is, liver regeneration, liver transplantation, or death. Results Twenty‐two children with PALF (body weight 2.5–106 kg) received 1–7 HVP cycles. No bleeding or procedure‐related mortality occurred. Alkalosis, hypothermia and reduction in platelets were observed. Haemolysis led to HVP termination in one infant. Seven children (32%) survived with their native livers, 13 patients (59%) underwent liver transplantation. Two infants died due to MOF. Overall survival was 86%. International normalization ratio (INR), alanine aminotransaminases (ALT), bilirubin and inotropic support were reduced significantly (p
pediatrics,gastroenterology & hepatology,nutrition & dietetics
What problem does this paper attempt to address?